NCT01533272View on ClinicalTrials.gov

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)

PHASE4CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions

HIV Infection

Interventions

DRUG

Tenofovir, emtricitabine, maraviroc

experimental drug

DRUG

Tenofovir, emtricitabine, lopinavir/r

Lopinavir/r 400mg BID

Trial Locations (1)

08036

Hospital Clinic de Barcelona, Barcelona

All Listed Sponsors

lead

Hospital Clinic of Barcelona

OTHER

NCT01533272 - Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) | Biotech Hunter | Biotech Hunter